ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption

Financial Performance - ImmunityBio reported a 700% year-over-year increase in net product revenue for its lead immunotherapy, ANKTIVA, reaching $113 million [1][4] - The company experienced a net loss of $351.4 million for the year, which was a reduction from 2024 losses, attributed to significant revenue offset and lower administrative expenses [2] Sales and Market Expansion - There was a 750% increase in unit sales volume for ANKTIVA, along with a 20% sequential growth in Q4, indicating strong clinical adoption [1] - ImmunityBio established a global commercial footprint with regulatory authorizations in 33 countries, including the US, UK, EU, and Saudi Arabia [2] Product Development and Partnerships - Saudi Arabia approved ANKTIVA for a second indication, metastatic non-small cell lung cancer, marking its first validation in solid tumors beyond bladder cancer [4] - The company formed partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in the Middle East, and established new subsidiaries in Dublin and Riyadh [4] Strategic Vision - ImmunityBio is advancing a three-year global strategy that positions ANKTIVA as the backbone for its Cancer BioShield platform, targeting various tumor types such as glioblastoma, pancreatic cancer, and lymphoma [4]